Profile nucleases and Repurpose Off-Targets to Expand Gene Editing

The PROTÉGÉ project aims to enhance gene editing safety and diversity by profiling programmable nucleases and exploring off-target effects for improved precision in genetic therapies.

Subsidie
€ 1.141.779
2023

Projectdetails

Introduction

Programmable nucleases reside at the nexus of advanced gene editing and microbial defense. These nucleases degrade phage DNA but avoid genomic DNA to provide the microbe with adaptive immunity. The standard-bearer, CRISPR-Cas9, relies on a guide RNA (gRNA) – its program – to precisely cut a complementary genetic sequence – its target – for precision gene editing.

Applications

These programmable nucleases deliver cures for genetic diseases like:

  • Anemia
  • Blindness
  • Cancer

They also facilitate quick disease model development and diagnostics for viruses like SARS-CoV-2.

Discovery of Nucleases

Hunts across microbial genomes have exposed thousands of programmable nucleases. Each could be another valuable tool for genome engineers, but we know just too little about them to use them safely.

Challenges with Off-Targets

Even Cas9 does not have guide-target parity: it cuts partially matched ‘off-target’ genome sites, which can lead to dangerous side effects. Though we work hard to avoid off-targets, partial matching may have a bright side.

Hypothesis

What if we leverage it, using it to make gene editing more predictable?

Research Program

Using high-throughput biochemistry, we will Profile nucleases and Repurpose Off-Targets to Expand Gene Editing. The PROTÉGÉ research program will:

  1. Profile guide-target parity – specificity – across promising, newly discovered programmable nucleases.
  2. Deliver a toolset for assessing this critical safety feature rapidly and broadly.
  3. Test the hypothesis that purposefully misprogramming nucleases can direct specific repair outcomes.

Conclusion

We intend to benefit Europe and the world community with safer and more diverse gene editing tools for achieving its Horizon Europe health, technology, and environmental goals.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 1.141.779
Totale projectbegroting€ 1.141.779

Tijdlijn

Startdatum1-6-2023
Einddatum31-5-2028
Subsidiejaar2023

Partners & Locaties

Projectpartners

  • VILNIAUS UNIVERSITETASpenvoerder

Land(en)

Lithuania

Vergelijkbare projecten binnen European Research Council

ERC STG

MANUNKIND: Determinants and Dynamics of Collaborative Exploitation

This project aims to develop a game theoretic framework to analyze the psychological and strategic dynamics of collaborative exploitation, informing policies to combat modern slavery.

€ 1.497.749
ERC STG

Elucidating the phenotypic convergence of proliferation reduction under growth-induced pressure

The UnderPressure project aims to investigate how mechanical constraints from 3D crowding affect cell proliferation and signaling in various organisms, with potential applications in reducing cancer chemoresistance.

€ 1.498.280
ERC STG

Uncovering the mechanisms of action of an antiviral bacterium

This project aims to uncover the mechanisms behind Wolbachia's antiviral protection in insects and develop tools for studying symbiont gene function.

€ 1.500.000
ERC STG

The Ethics of Loneliness and Sociability

This project aims to develop a normative theory of loneliness by analyzing ethical responsibilities of individuals and societies to prevent and alleviate loneliness, establishing a new philosophical sub-field.

€ 1.025.860

Vergelijkbare projecten uit andere regelingen

ERC COG

In Vivo CRISPR-Based Nanoplatform for Gene Editing: A New Disruptive Avenue for Non-Invasive Treatment of Genetic Brain Diseases

This project aims to develop a novel nanoplatform for the safe and efficient delivery of CRISPR gene editing technology to treat genetic brain diseases non-invasively.

€ 2.249.895
EIC Pathfinder

New Prime Editing and non-viral delivery strategies for Gene Therapy

This project aims to develop non-viral delivery systems and novel prime editors to enhance gene editing efficiency and safety for treating Sickle Cell Disease and other genetic disorders.

€ 4.406.097
ERC ADG

Repurposing of CAST Systems as Next-Generation Tools for Genome Engineering of Mammalian Cells

INTETOOLS aims to enhance genome engineering by repurposing CRISPR Associated Transposon systems for precise insertion of large DNA cargos in eukaryotic genomes, overcoming current limitations.

€ 2.475.491
ERC POC

Harnessing a novel CRISPR nuclease for programmable counterselection in human cells

This project aims to enhance CRISPR genome editing efficiency by developing a programmable counter-selection mechanism to eliminate unedited cells, thereby reducing screening burdens in various applications.

€ 150.000